Merit Medical Systems Inc (MMSI)
101.97
-0.51
(-0.50%)
USD |
NASDAQ |
Nov 07, 16:00
102.01
+0.04
(+0.04%)
After-Hours: 20:00
Merit Medical Systems Revenue (Annual): 1.257B for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 1.257B |
December 31, 2022 | 1.151B |
December 31, 2021 | 1.075B |
December 31, 2020 | 963.88M |
December 31, 2019 | 994.85M |
December 31, 2018 | 882.75M |
December 31, 2017 | 727.85M |
December 31, 2016 | 603.84M |
December 31, 2015 | 542.15M |
December 31, 2014 | 509.69M |
December 31, 2013 | 449.05M |
December 31, 2012 | 394.29M |
December 31, 2011 | 359.45M |
December 31, 2010 | 296.76M |
December 31, 2009 | 257.46M |
December 31, 2008 | 227.14M |
December 31, 2007 | 207.77M |
December 31, 2006 | 190.67M |
Date | Value |
---|---|
December 31, 2005 | 166.58M |
December 31, 2004 | 151.40M |
December 31, 2003 | 135.95M |
December 31, 2002 | 116.23M |
December 31, 2001 | 104.04M |
December 31, 2000 | 91.45M |
December 31, 1999 | 78.00M |
December 31, 1998 | 68.40M |
December 31, 1997 | 60.60M |
December 31, 1996 | 50.50M |
December 31, 1995 | 42.60M |
December 31, 1994 | 33.30M |
December 31, 1993 | 25.40M |
December 31, 1992 | 18.40M |
December 31, 1991 | 10.50M |
December 31, 1990 | 4.40M |
December 31, 1989 | 1.40M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
963.88M
Minimum
2020
1.257B
Maximum
2023
1.088B
Average
1.075B
Median
2021
Revenue (Annual) Benchmarks
Boston Scientific Corp | 14.24B |
Abbott Laboratories | 40.11B |
Baxter International Inc | 14.81B |
Becton Dickinson & Co | 19.37B |
Perspective Therapeutics Inc | -- |